Fmr LLC Kodiak Sciences Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Fmr LLC holds 158,984 shares of KOD stock, worth $410,178. This represents 0.0% of its overall portfolio holdings.

Number of Shares

158,984

Previous 154,109 3.16%

Holding current value

$410,178

Previous $810,000 53.95%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.29 - $4.48 $11,163 - $21,840	4,875 Added 3.16%	158,984 $373,000
Q1 2024 May 13, 2024	BUY	$3.01 - $7.45 $6,302 - $15,600	2,094 Added 1.38%	154,109 $810,000
Q4 2023 Feb 13, 2024	BUY	$1.4 - $3.24 $28,166 - $65,185	20,119 Added 15.25%	152,015 $462,000
Q3 2023 Nov 13, 2023	BUY	$1.8 - $7.49 $131,787 - $548,380	73,215 Added 124.77%	131,896 $237,000
Q2 2023 Aug 11, 2023	BUY	$4.3 - $9.48 $8 - $18	2 Added 0.0%	58,681 $404,000
Q1 2023 May 11, 2023	SELL	$4.81 - $8.88 $8,648 - $15,966	-1,798 Reduced 2.97%	58,679 $363,000
Q4 2022 Feb 13, 2023	SELL	$6.52 - $8.05 $8,534 - $10,537	-1,309 Reduced 2.12%	60,477 $433,000
Q3 2022 Nov 10, 2022	BUY	$7.57 - $12.5 $451,505 - $745,550	59,644 Added 2784.5%	61,786 $478,000
Q2 2022 Aug 12, 2022	BUY	$5.04 - $9.48 $8,391 - $15,784	1,665 Added 349.06%	2,142 $16,000
Q1 2022 May 13, 2022	SELL	$7.09 - $89.45 $1.66 Million - $20.9 Million	-233,991 Reduced 99.8%	477 $4,000
Q3 2021 Nov 15, 2021	SELL	$81.97 - $106.94 $11.7 Million - $15.2 Million	-142,400 Reduced 37.79%	234,468 $22.5 Million
Q2 2021 Aug 13, 2021	BUY	$77.2 - $126.54 $29.1 Million - $47.7 Million	376,868 New	376,868 $35 Million

Others Institutions Holding KOD

# of Institutions

104

Shares Held

39.8M

Call Options Held

7.6K

Put Options Held

3.5K

View Full List

About Kodiak Sciences Inc.

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $134M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

More about KOD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account